Abstract
Deterioration of hematologic parameters in lymphoma patients is often attributed to disease progression, comorbidities, or treatment effects. Second primary malignancies occur at increased frequency in CLL and must also be considered.
Keywords: chronic lymphocytic leukemia, composite lymphoma
Deterioration of hematologic parameters in lymphoma patients is often attributed to disease progression, comorbidities, or treatment effects. Second primary malignancies occur at increased frequency in CLL and must also be considered.
1. INTRODUCTION
A 73‐year‐old woman with a long‐standing history of untreated chronic lymphocytic leukemia (CLL) presented with fatigue and progressive anemia. A bone marrow biopsy was performed for suspicion of disease progression and exclusion of alternative conditions.
Her peripheral blood showed atypical lymphocytes with dimorphic cytologic features (Figure 1, panels A‐B) including a subset of intermediate‐sized cells with expanded cytoplasm (arrows). Her bone marrow was involved by nodular aggregates (Figure 1, panel C) of composite lymphoma consisting of two morphologically and immunophenotypically distinct populations of abnormal B lymphocytes: small mature cells (Figure 1, panel D, lower right) consistent with her known CLL and a surrounding population of larger cells with more open chromatin and distinct nucleoli (Figure 1, panel D, upper left) and antigen expression most suggestive of marginal zone or lymphoplasmacytic lymphoma.
Figure 1.
Peripheral blood film (A‐B, 60× objective) with dimorphic atypical lymphocytes and bone marrow biopsy (C, 10× objective; D, 100× objective) with nodular lymphoid infiltrates accounting for the majority of marrow cellularity. Two distinct B‐cell populations differentially express CD5, CD20, CD79, and sIg by immunohistochemistry (E‐F, 4× objective; G, 10× objective; H, 100× objective) and/or flow cytometry (I‐L, magenta: CLL; blue: second primary non‐Hodgkin lymphoma)
The risk of developing a second primary malignancy is more than twice as high in patients with CLL than those without and must be considered in the setting of emerging cytopenias.1 Among secondary hematologic malignancies, most of this excess risk is due to additional non‐Hodgkin lymphomas.2 In this case, the patient's worsening anemia was attributed to the combination of her new secondary non‐Hodgkin lymphoma in composite with her known CLL.
CONFLICT OF INTEREST
The authors have no conflicts of interest to disclose.
AUTHOR CONTRIBUTIONS
EM: captured images and prepared the manuscript. JTE, JWC, and HMR: analyzed the case, provided images, and participated in preparation and revision of the manuscript.
McGinnis E, England JT, Craig JW, Moshref Razavi H. Chronic lymphocytic leukemia with progressive anemia secondary to development of composite lymphoma. Clin Case Rep. 2020;8:396–397. 10.1002/ccr3.2656
REFERENCES
- 1. Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27(6):904‐910. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Kumar V, Ailawadhi S, Bojanini L, et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019;9(10):75. [DOI] [PMC free article] [PubMed] [Google Scholar]